Cover Image
Market Research Report
Product code 
1066890

U.S. Gene Therapy Market - Industry Outlook & Forecast 2022-2027

Published: | Arizton Advisory & Intelligence | 208 Pages | Delivery time: 1-2 business days

Price

Back to Top
U.S. Gene Therapy Market - Industry Outlook & Forecast 2022-2027
Published: March 24, 2022
Arizton Advisory & Intelligence
Content info: 208 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this U.S. Gene Therapy Market Report

The market is witnessing steady growth due to the increased availability of funding from various public and private institutes. In addition, there is increased support from regulatory bodies for product approvals and providing fast-track designations to the products, which encourages vendors to manufacture the products at a faster rate.

U.S. gene therapy market is expected to grow at a CAGR of 43.44% during 2022-2027

MARKET OPPORTUNITIES AND TRENDS

  • Increasing Market Access for Gene Therapies
  • Introduction Of Universal Car-T Therapy
  • Increase In Strategic Acquisitions
  • Increased Funding For R&D Activities of Gene Therapies

The US gene therapy market would realize an absolute growth of over 771.00% in terms of revenue between 2021 and 2027.

U.S. GENE THERAPY MARKET SEGMENTATION

Among product type segments, the CAR-T therapy segment dominates the US gene therapy market, accounting for a share of 51.96%, followed by non-CAR-T therapy with 48.04% in 2021.

Based on the vector type, the US gene therapy market is segmented into retroviral and others. The other segment includes adeno virus, adeno-associated virus, herpes simplex virus, and non-viral vectors. The retroviral segment accounted for a major share of 51.96% and others with 48.04% in 2021

Based on end-users, the market is segmented into hospitals, cancer care centers, and academic & research centers. The hospital segment dominated the market with a share of 56.45%, followed by cancer care centers with 35.87%.

Market Segmentation by Vector Type

  • Retroviral
  • Others

Market Segmentation by Product Type

  • Car T Therapy
  • Non-Car T Therapy

Market Segmentation by Indication

  • Oncology
  • Others

Market Segmentation by Gene Transfer

  • Ex-Vivo
  • In-Vivo

Market Segmentation by End User

  • Hospitals
  • Cancer Care Centers
  • Academic & Research Centers

VENDOR ANALYSIS

The US gene therapy market is witnessing the high competition among the vendors. The market is characterized by the presence of various pharma and various small-scale companies. With the changing market landscape, the competition is turning intense due to some recent high-value M&As.

Key Vendors

  • Amgen
  • bluebird bio
  • Bristol Myers Squibb
  • Gilead Sciences
  • Novartis
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • 4DMT
  • Abeona Therapeutics
  • AnGes
  • AskBio
  • Astellas Gene Therapies
  • Autolus Therapeutics
  • Candel Therapeutics
  • Castle Creek Biosciences
  • Cellectis
  • Evox Therapeutics
  • Freeline Therapeutics
  • Gene Biotherapeutics
  • Generation Bio
  • GenSight Biologics
  • Helixmith
  • Janssen Pharmaceuticals
  • Kolon Tissue Gene
  • Krystal Biotech
  • MeiraGTx
  • Orchard Therapeutics
  • Pfizer
  • Poseida Therapeutics
  • Passage Bio
  • RegenxBio
  • Sana Biotechnology
  • Sarepta Therapeutics
  • StrideBio
  • Solid Biosciences
  • VBL Therapeutics
  • Voyager Therapeutics
  • Uniqure

THE REPORT INCLUDES:

  • 1. The analysis of the U.S. Gene Therapy market size and growth rate for the forecast period 2022-2027.
  • 2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the U.S. Gene Therapy market.
  • 3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
  • 4. It offers a complete overview of market segments and the regional outlook of the Gene Therapy market.
  • 5. The report offers a detailed overview of the vendor landscape, competitive analysis, and critical market strategies to gain competitive advantage.
Product Code: ARZ220236

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
  • 4.1.1 INCLUSIONS
  • 4.1.2 EXCLUSIONS
  • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
  • 4.3.1 MARKET SEGMENTATION BY VECTOR
  • 4.3.2 MARKET SEGMENTATION BY PRODUCT
  • 4.3.3 MARKET SEGMENTATION BY INDICATION
  • 4.3.4 MARKET SEGMENTATION BY GENE TRANSFER
  • 4.3.5 MARKET SEGMENTATION BY END-USERS

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 BACKGROUND
  • 7.2 GENE THERAPY: AN OVERVIEW
  • 7.2.1 EVOLUTION OF GENE THERAPY

8 REIMBURSEMENT FOR GENE THERAPY IN US

  • 8.1 OVERVIEW

9 REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS

  • 9.1 OVERVIEW
  • 9.2 CLINICAL TRIAL PROCESS FOR GENE THERAPY

10 COMMERCIAL GENE THERAPY PRODUCTS IN US

  • 10.1 OVERVIEW
  • 10.1.1 ABECMA (IDECABTAGENE VICLEUCEL)
  • 10.1.2 BREYANZI (LISOCABTAGENE MARALEUCEL)
  • 10.1.3 TECARTUS (BREXUCABTAGENE AUTOLEUCEL)
  • 10.1.4 ZOLGENSMA (ONASEMNOGENE ABEPARVOVEC)
  • 10.1.5 LUXTURNA (VORETIGENE NEPARVOVEC)
  • 10.1.6 YESCARTA (AXICABTAGENE CILOLEUCEL)
  • 10.1.7 KYMRIAH (TISAGENLECLEUCEL-T)
  • 10.1.8 IMLYGIC (TALIMOGENE LAHERPAREPVEC)

11 GENE THERAPY PRODUCTS IN PIPELINE

  • 11.1 OVERVIEW

12 MARKET OPPORTUNITIES & TRENDS

  • 12.1 INCREASING MARKET ACCESS FOR GENE THERAPIES
  • 12.2 INTRODUCTION OF UNIVERSAL CAR-T THERAPY
  • 12.3 INCREASE IN STRATEGIC ACQUISITIONS
  • 12.4 INCREASED FUNDING FOR R&D ACTIVITIES OF GENE THERAPIES

13 MARKET GROWTH ENABLERS

  • 13.1 INCREASE IN CMOS TO MANUFACTURE GENE THERAPIES
  • 13.2 INCREASING TARGET PATIENT POPULATION
  • 13.3 PRODUCT LAUNCHES & REGULATORY APPROVALS
  • 13.4 REGULATORY SUPPORT & SPECIAL DESIGNATIONS FOR GENE THERAPIES

14 MARKET RESTRAINTS

  • 14.1 HIGH COST OF GENE THERAPY PRODUCTS
  • 14.2 LIMITATIONS OF GENE THERAPY PRODUCTS
  • 14.3 AVAILABILITY OF ALTERNATIVE THERAPEUTICS & WITHDRAWAL OF PRODUCTS

15 MARKET LANDSCAPE

  • 15.1 MARKET OVERVIEW
  • 15.2 MARKET SIZE & FORECAST
  • 15.2.1 INSIGHTS BY VECTOR TYPE
  • 15.2.2 INSIGHTS BY PRODUCT TYPE
  • 15.2.3 INSIGHTS BY INDICATION TYPE
  • 15.2.4 INSIGHTS BY GENE TRANSFER TYPE
  • 15.2.5 INSIGHTS BY END-USERS
  • 15.3 FIVE FORCES ANALYSIS
  • 15.3.1 THREAT OF NEW ENTRANTS
  • 15.3.2 BARGAINING POWER OF SUPPLIERS
  • 15.3.3 BARGAINING POWER OF BUYERS
  • 15.3.4 THREAT OF SUBSTITUTES
  • 15.3.5 COMPETITIVE RIVALRY

16 VECTOR TYPE

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 MARKET OVERVIEW
  • 16.3 RETROVIRAL
  • 16.3.1 MARKET OVERVIEW
  • 16.3.2 MARKET SIZE & FORECAST
  • 16.4 OTHER VECTORS
  • 16.4.1 MARKET OVERVIEW
  • 16.4.2 MARKET SIZE & FORECAST

17 PRODUCT TYPE

  • 17.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 17.2 MARKET OVERVIEW
  • 17.3 CAR-T THERAPY
  • 17.3.1 MARKET OVERVIEW
  • 17.3.2 MARKET SIZE & FORECAST
  • 17.4 NON-CAR-T THERAPY
  • 17.4.1 MARKET OVERVIEW
  • 17.4.2 MARKET SIZE & FORECAST

18 INDICATION

  • 18.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 18.2 MARKET OVERVIEW
  • 18.3 ONCOLOGY
  • 18.3.1 MARKET OVERVIEW
  • 18.3.2 MARKET SIZE & FORECAST
  • 18.4 OTHERS
  • 18.4.1 MARKET OVERVIEW
  • 18.4.2 MARKET SIZE & FORECAST

19 GENE TRANSFER

  • 19.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 19.2 MARKET OVERVIEW
  • 19.3 EX-VIVO
  • 19.3.1 MARKET OVERVIEW
  • 19.3.2 MARKET SIZE & FORECAST
  • 19.4 IN-VIVO
  • 19.4.1 MARKET OVERVIEW
  • 19.4.2 MARKET SIZE & FORECAST

20 END-USERS

  • 20.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 20.2 MARKET OVERVIEW
  • 20.3 HOSPITALS
  • 20.3.1 MARKET OVERVIEW
  • 20.3.2 MARKET SIZE & FORECAST
  • 20.4 CANCER CARE CENTERS
  • 20.4.1 MARKET OVERVIEW
  • 20.4.2 MARKET SIZE & FORECAST
  • 20.5 ACADEMIC & RESEARCH CENTERS
  • 20.5.1 MARKET OVERVIEW
  • 20.5.2 MARKET SIZE & FORECAST

21 COMPETITIVE LANDSCAPE

  • 21.1 COMPETITION OVERVIEW
  • 21.2 MARKET SHARE ANALYSIS
  • 21.2.1 AMGEN
  • 21.2.2 BLUEBIRD BIO
  • 21.2.3 BRISTOL MYERS SQUIBB
  • 21.2.4 GILEAD SCIENCES
  • 21.2.5 NOVARTIS
  • 21.2.6 F. HOFFMANN-LA ROCHE

22 KEY COMPANY PROFILES

  • 22.1 AMGEN
  • 22.1.1 BUSINESS OVERVIEW
  • 22.1.2 PRODUCT OFFERINGS
  • 22.1.3 KEY STRATEGIES
  • 22.1.4 KEY STRENGTHS
  • 22.1.5 KEY OPPORTUNITIES
  • 22.2 BLUEBIRD BIO
  • 22.2.1 BUSINESS OVERVIEW
  • 22.2.2 PRODUCT OFFERINGS
  • 22.2.3 KEY STRATEGIES
  • 22.2.4 KEY STRENGTHS
  • 22.2.5 KEY OPPORTUNITIES
  • 22.3 BRISTOL MYERS SQUIBB
  • 22.3.1 BUSINESS OVERVIEW
  • 22.3.2 PRODUCT OFFERINGS
  • 22.3.3 KEY STRATEGIES
  • 22.3.4 KEY STRENGTHS
  • 22.3.5 KEY OPPORTUNITIES
  • 22.4 GILEAD SCIENCES
  • 22.4.1 BUSINESS OVERVIEW
  • 22.4.2 PRODUCT OFFERINGS
  • 22.4.3 KEY STRATEGIES
  • 22.4.4 KEY STRENGTHS
  • 22.4.5 KEY OPPORTUNITIES
  • 22.5 NOVARTIS
  • 22.5.1 BUSINESS OVERVIEW
  • 22.5.2 PRODUCT OFFERINGS
  • 22.5.3 KEY STRATEGIES
  • 22.5.4 KEY STRENGTHS
  • 22.5.5 KEY OPPORTUNITIES
  • 22.6 F. HOFFMANN-LA ROCHE
  • 22.6.1 BUSINESS OVERVIEW
  • 22.6.2 PRODUCT OFFERINGS
  • 22.6.3 KEY STRATEGIES
  • 22.6.4 KEY STRENGTHS
  • 22.6.5 KEY OPPORTUNITIES

23 GENE THERAPY INVESTIGATIONAL COMPANIES

  • 23.1 4DMT
  • 23.1.1 BUSINESS OVERVIEW
  • 23.2 ABEONA THERAPEUTICS
  • 23.2.1 BUSINESS OVERVIEW
  • 23.3 ANGES
  • 23.3.1 BUSINESS OVERVIEW
  • 23.4 ASKBIO
  • 23.4.1 BUSINESS OVERVIEW
  • 23.5 ASTELLAS GENE THERAPIES
  • 23.5.1 BUSINESS OVERVIEW
  • 23.6 AUTOLUS THERAPEUTICS
  • 23.6.1 BUSINESS OVERVIEW
  • 23.7 CANDEL THERAPEUTICS
  • 23.7.1 BUSINESS OVERVIEW
  • 23.8 CASTLE CREEK BIOSCIENCES
  • 23.8.1 BUSINESS OVERVIEW
  • 23.9 CELLECTIS
  • 23.9.1 BUSINESS OVERVIEW
  • 23.10 EVOX THERAPEUTICS
  • 23.10.1 BUSINESS OVERVIEW
  • 23.11 FREELINE THERAPEUTICS
  • 23.11.1 BUSINESS OVERVIEW
  • 23.12 GENE BIOTHERAPEUTICS
  • 23.12.1 BUSINESS OVERVIEW
  • 23.13 GENERATION BIO
  • 23.13.1 BUSINESS OVERVIEW
  • 23.14 GENSIGHT BIOLOGICS
  • 23.14.1 BUSINESS OVERVIEW
  • 23.15 HELIXMITH
  • 23.15.1 BUSINESS OVERVIEW
  • 23.16 JANSSEN PHARMACEUTICALS
  • 23.16.1 BUSINESS OVERVIEW
  • 23.17 KOLON TISSUE GENE
  • 23.17.1 BUSINESS OVERVIEW
  • 23.18 KRYSTAL BIOTECH
  • 23.18.1 BUSINESS OVERVIEW
  • 23.19 MEIRAGTX
  • 23.19.1 BUSINESS OVERVIEW
  • 23.20 ORCHARD THERAPEUTICS
  • 23.20.1 BUSINESS OVERVIEW
  • 23.21 PFIZER
  • 23.21.1 BUSINESS OVERVIEW
  • 23.22 POSEIDA THERAPEUTICS
  • 23.22.1 BUSINESS OVERVIEW
  • 23.23 PASSAGE BIO
  • 23.23.1 BUSINESS OVERVIEW
  • 23.24 REGENXBIO
  • 23.24.1 BUSINESS OVERVIEW
  • 23.25 SANA BIOTECHNOLOGY
  • 23.25.1 BUSINESS OVERVIEW
  • 23.26 SAREPTA THERAPEUTICS
  • 23.26.1 BUSINESS OVERVIEW
  • 23.27 STRIDEBIO
  • 23.27.1 BUSINESS OVERVIEW
  • 23.28 SOLID BIOSCIENCES
  • 23.28.1 BUSINESS OVERVIEW
  • 23.29 VBL THERAPEUTICS
  • 23.29.1 BUSINESS OVERVIEW
  • 23.30 VOYAGER THERAPEUTICS
  • 23.30.1 BUSINESS OVERVIEW
  • 23.31 UNIQURE
  • 23.31.1 BUSINESS OVERVIEW

24 REPORT SUMMARY

  • 24.1 KEY TAKEAWAYS
  • 24.2 STRATEGIC RECOMMENDATIONS

25 QUANTITATIVE SUMMARY

  • 25.1 MARKET BY VECTOR TYPE
  • 25.2 MARKET BY PRODUCT TYPE
  • 25.3 MARKET BY INDICATION
  • 25.4 MARKET BY GENE TRANSFER
  • 25.5 MARKET BY END-USER

26 APPENDIX

  • 26.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF US GENE THERAPY MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021

EXHIBIT 3 CLASSIFICATION OF REGENERATIVE MEDICINE

EXHIBIT 4 PAST & PRESENT GENERATIONS OF GENE THERAPY

EXHIBIT 5 PROCESS OF GENE THERAPY

EXHIBIT 6 HISTORY OF GENE THERAPY NIH-FDA OVERSIGHT

EXHIBIT 7 PROCESS OF CLINICAL TRIALS FOR GENE THERAPY PRODUCTS

EXHIBIT 8 FDA-APPROVED COMMERCIALIZED GENE THERAPY PRODUCTS IN THE US

EXHIBIT 9 IMPACT OF INCREASING MARKET ACCESS FOR GENE THERAPIES

EXHIBIT 10 IMPACT OF INTRODUCTION OF UNIVERSAL CAR-T THERAPY

EXHIBIT 11 IMPACT OF INCREASE IN STRATEGIC ACQUISITIONS

EXHIBIT 12 IMPACT OF INCREASED FUNDING FOR R&D ACTIVITIES OF GENE THERAPIES

EXHIBIT 13 IMPACT OF INCREASE IN CMOS TO MANUFACTURE GENE THERAPIES

EXHIBIT 14 MAJOR ADVANTAGES BY ENGAGING WITH CMOS

EXHIBIT 15 FACTORS CONSIDERED ON PARTNERSHIP WITH CONTRACT MANUFACTURERS

EXHIBIT 16 IMPACT OF INCREASING TARGET PATIENT POPULATION

EXHIBIT 17 IMPACT OF PRODUCT LAUNCHES & REGULATORY APPROVALS

EXHIBIT 18 IMPACT OF REGULATORY SUPPORT & SPECIAL DESIGNATIONS FOR GENE THERAPIES

EXHIBIT 19 CUMULATIVE NUMBER OF RMAT REQUESTS RECEIVED BY FDA 2017-2022

EXHIBIT 20 IMPACT OF HIGH COST OF GENE THERAPY PRODUCTS

EXHIBIT 21 IMPACT OF LIMITATIONS OF GENE THERAPY PRODUCTS

EXHIBIT 22 IMPACT OF AVAILABILITY OF ALTERNATIVE THERAPEUTICS & WITHDRAWAL OF PRODUCTS

EXHIBIT 23 US GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 24 US GENE THERAPY MARKET BY VECTOR TYPE: MARKET SHARE 2021 & 2027

EXHIBIT 25 US GENE THERAPY MARKET BY PRODUCT: MARKET SHARE 2021 & 2027

EXHIBIT 26 US GENE THERAPY MARKET BY INDICATION: MARKET SHARE 2021 & 2027

EXHIBIT 27 US GENE THERAPY MARKET BY GENE TRANSFER: MARKET SHARE 2021 & 2027

EXHIBIT 28 US GENE THERAPY MARKET BY END-USERS: MARKET SHARE 2021 & 2027

EXHIBIT 29 FIVE FORCES ANALYSIS 2021

EXHIBIT 30 INCREMENTAL GROWTH BY VECTOR TYPE 2021 & 2027

EXHIBIT 31 US GENE THERAPY MARKET BY VECTOR TYPE

EXHIBIT 32 TYPES OF VECTORS USED IN GENE THERAPY

EXHIBIT 33 US GENE THERAPY MARKET BY VECTOR TYPE: INCREMENTAL GROWTH

EXHIBIT 34 US GENE THERAPY MARKET BY VECTOR TYPE: ABSOLUTE GROWTH

EXHIBIT 35 US RETROVIRAL GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 36 US RETROVIRAL GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 37 NON-VIRAL VECTOR SYSTEMS USED FOR GENE TRANSFER

EXHIBIT 38 US OTHER VECTORS GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 39 US OTHER VECTORS GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 40 INCREMENTAL GROWTH BY PRODUCT TYPE 2021 & 2027

EXHIBIT 41 US GENE THERAPY MARKET BY PRODUCT TYPE

EXHIBIT 42 US GENE THERAPY MARKET BY PRODUCT TYPE: INCREMENTAL GROWTH

EXHIBIT 43 US GENE THERAPY MARKET BY PRODUCT TYPE: ABSOLUTE GROWTH

EXHIBIT 44 US CAR-T GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 45 US CAR-T GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 46 US NON-CAR-T GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 47 US NON-CAR-T GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 48 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 49 US GENE THERAPY MARKET BY INDICATION TYPE

EXHIBIT 50 US GENE THERAPY MARKET BY INDICATION: INCREMENTAL GROWTH

EXHIBIT 51 US GENE THERAPY MARKET BY INDICATION: ABSOLUTE GROWTH

EXHIBIT 52 US ONCOLOGY GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 53 US ONCOLOGY GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 54 US OTHER INDICATIONS GENE THERAPY MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 55 US OTHER INDICATIONS GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 56 INCREMENTAL GROWTH BY GENE TRANSFER 2021 & 2027

EXHIBIT 57 US GENE THERAPY MARKET BY GENE TRANSFER TYPE

EXHIBIT 58 US GENE THERAPY MARKET BY GENE TRANSFER: INCREMENTAL GROWTH

EXHIBIT 59 US GENE THERAPY MARKET BY GENE TRANSFER: ABSOLUTE GROWTH

EXHIBIT 60 US EX-VIVO GENE THERAPY MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 61 US EX-VIVO GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 62 US IN-VIVO GENE THERAPY MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 63 US IN-VIVO GENE THERAPY MARKET 2021-2027 ($ MILLION)

EXHIBIT 64 INCREMENTAL GROWTH BY END-USERS 2021 & 2027

EXHIBIT 65 US GENE THERAPY MARKET BY END-USERS

EXHIBIT 66 US GENE THERAPY MARKET BY END-USERS: INCREMENTAL GROWTH

EXHIBIT 67 US GENE THERAPY MARKET BY END-USERS: ABSOLUTE GROWTH

EXHIBIT 68 US GENE THERAPY MARKET BY HOSPITALS: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 69 US GENE THERAPY MARKET BY HOSPITALS 2021-2027 ($ MILLION)

EXHIBIT 70 US GENE THERAPY MARKET BY CANCER CARE CENTERS: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 71 US GENE THERAPY MARKET BY CANCER CARE CENTERS 2021-2027 ($ MILLION)

EXHIBIT 72 US GENE THERAPY MARKET BY ACADEMIC & RESEARCH INSTITUTES: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 73 US GENE THERAPY MARKET BY ACADEMIC & RESEARCH CENTERS 2021-2027 ($ MILLION)

EXHIBIT 74 PURE & DIVERSIFIED VENDORS IN US GENE THERAPY MARKET

EXHIBIT 75 AMGEN: TOTAL REVENUE 2018-2020 ($ MILLION)

EXHIBIT 76 AMGEN: R&D EXPENDITURE 2018-2020 ($ MILLION)

EXHIBIT 77 BLUEBIRD BIO: TOTAL REVENUE 2018-2020 ($ MILLION)

EXHIBIT 78 BLUEBIRD BIO: R&D EXPENDITURE 2018-2020 ($ MILLION)

EXHIBIT 79 BRISTOL MYERS SQUIBB: TOTAL REVENUE 2019-2021 ($ MILLION)

EXHIBIT 80 BRISTOL MYERS SQUIBB: R&D EXPENDITURE 2019-2021 ($ MILLION)

EXHIBIT 81 BRISTOL MYERS SQUIBB: REVENUE BY GEOGRAPHIC REGIONS 2021 ($ MILLION)

EXHIBIT 82 GILEAD SCIENCES: TOTAL REVENUE 2018-2020 ($ MILLION)

EXHIBIT 83 GILEAD SCIENCES: R&D EXPENDITURE 2018-2020 ($ MILLION)

EXHIBIT 84 NOVARTIS: TOTAL REVENUE 2018-2020 ($ MILLION)

EXHIBIT 85 NOVARTIS: R&D EXPENDITURE 2018-2020 ($ MILLION)

EXHIBIT 86 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2019-2020 ($ MILLION)

EXHIBIT 87 NOVARTIS: REVENUE BY GEOGRAPHY 2020 ($ MILLION)

EXHIBIT 88 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2019-2021 ($ BILLION)

EXHIBIT 89 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019-2021 ($ BILLION)

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015-2021

TABLE 3 MAJOR FINANCING CHALLENGES EXIST FOR PAYERS

TABLE 4 EXAMPLES OF GENE THERAPIES LAUNCHED IN US ASSOCIATED WITH HIGH COSTS

TABLE 5 EXEMPLARS OF INNOVATIVE PAYMENT MECHANISMS USED FOR GENE THERAPIES IN US

TABLE 6 GENE THERAPY CLINICAL TRIAL STATUS IN US MARKET

TABLE 7 GENE THERAPY CLINICAL TRIALS IN DIFFERENT PHASES IN US MARKET

TABLE 8 GENE THERAPY CLINICAL TRIALS ENROLLMENT STATUS IN US MARKET

TABLE 9 GENE THERAPY PRODUCTS IN PIPELINE & EXPECTED YEAR OF LAUNCH

TABLE 10 PHARMACEUTICAL COMPANIES & NON-PROFIT ORGANIZATIONS FOR DEVELOPMENT AND UNLOCKING ACCESS TO GENE THERAPIES

TABLE 11 RECENT STRATEGIC ACQUISITIONS IN GENE THERAPY MARKET

TABLE 12 FUNDING OF GENE THERAPY CLINICAL TRIALS LISTED IN 2020

TABLE 13 MAJOR INVESTMENTS BY CMOS IN GENE THERAPY DEVELOPMENT

TABLE 14 TARGET POPULATION & RESPECTIVE GENE THERAPY IN US AS OF 2021

TABLE 15 PRODUCT APPROVALS & LAUNCH DETAILS

TABLE 16 OVERVIEW OF ALL FOUR FDA'S EXPEDITED PROGRAMS

TABLE 17 LIST OF PRODUCTS THAT RECEIVED RMAT DESIGNATION

TABLE 18 COST OF KYMRIAH IN DIFFERENT REGIONS

TABLE 19 FDA APPROVED CAR-T THERAPIES IN THE US

TABLE 20 FDA APPROVED NON-CAR-T THERAPIES IN US

TABLE 21 GENE THERAPY PRODUCTS AVAILABLE FOR CANCER IN US

TABLE 22 GENE THERAPY PRODUCTS AVAILABLE FOR GENETIC DISORDERS IN US

TABLE 23 TOP CANCER CARE CENTERS ACROSS US

TABLE 24 VENDORS OFFERING COMMERCIAL GENE THERAPY PRODUCTS IN US: MARKET DOMINANCE ANALYSIS

TABLE 25 VENDORS OFFERING COMMERCIAL GENE THERAPY PRODUCTS IN US: CAPABILITIES & EXPERTISE ASSESSMENT

TABLE 26 US GENE THERAPY MARKET: VENDOR RANKING

TABLE 27 AMGEN: MAJOR PRODUCT OFFERINGS

TABLE 28 BLUEBIRD BIO: MAJOR PRODUCT OFFERINGS

TABLE 29 BRISTOL MYERS SQUIBB: MAJOR PRODUCT OFFERINGS

TABLE 30 GILEAD SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 31 NOVARTIS: MAJOR PRODUCT OFFERINGS

TABLE 32 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS

TABLE 33 US GENE THERAPY MARKET BY VECTOR TYPE 2021-2027 ($ MILLION)

TABLE 34 US GENE THERAPY MARKET BY VECTOR TYPE 2021-2027 (%)

TABLE 35 US GENE THERAPY MARKET BY PRODUCT TYPE 2021-2027 ($ MILLION)

TABLE 36 US GENE THERAPY MARKET BY PRODUCT TYPE 2021-2027 (%)

TABLE 37 US GENE THERAPY MARKET BY INDICATION 2021-2027 ($ MILLION)

TABLE 38 US GENE THERAPY MARKET BY INDICATION 2021-2027 (%)

TABLE 39 US GENE THERAPY MARKET BY GENE TRANSFER 2021-2027 ($ MILLION)

TABLE 40 US GENE THERAPY MARKET BY GENE TRANSFER 2021-2027 (%)

TABLE 41 US GENE THERAPY MARKET BY END-USER 2021-2027 ($ MILLION)

TABLE 42 US GENE THERAPY MARKET BY END-USER 2021-2027 (%)